Vir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment

Reuters

2025/07/31

<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment

Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta $(CHD)$. The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus $(HDV)$ RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250731294819) on July 31, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2555838315"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555838315\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555838315?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555838315","market":"fut","top_or_hot":-1,"title":"Vir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta <a href=\"https://laohu8.com/S/CHD\">$(CHD)$</a>. The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250731294819) on July 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-31 20:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta <a href=\"https://laohu8.com/S/CHD\">$(CHD)$</a>. The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250731294819) on July 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDLtr9Rl:1","article_id":"2555838315","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555838315","pubTimestamp":1753963543,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta . The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus  RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4535":"淡马锡持仓","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","VIR":"Vir Biotechnology, Inc."},"translate_title":"Vir Biotechnology启动慢性δ型肝炎治疗3期ECLIPSE 2试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"Vir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment\n    \n\n        Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta $(CHD)$. The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus $(HDV)$ RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250731294819) on July 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}